Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. How we score this
23 firms currently rating it, weighted by track record.
The 22 firms with a track record here beat the S&P 43% of the time over 12 months.
Pro: see the crowd-vs-sharp split for MRKAnalysts rate Merck with a consensus Buy from 26 firms, with an average price target of $152.96, implying 5.6% upside from the current $144.85. The most recent rating action came on September 10 when HSBC maintained its Buy rating. Merck trades at a trailing P/E of 115.88 but a forward P/E of 15.17, with revenue growing 5.10% year-over-year and a gross margin of 75.90%. The stock carries a low beta of 0.23 and trades near its 52-week high of $156.92, well above its 52-week low of $77.58.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 10, 2026 | HSBC | ○ Maintained | |
| Sep 9, 2026 | Leerink Partners | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free